secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0001104659-22-069168
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

President/CMO Michael Goldstein to depart June 30; Rabia Ozden named new CMO
----------------------------------------------------------------------------

- Michael Goldstein, President Ophthalmology and CMO, leaves OCUL on June 30, 2022.
- Rabia Gurses Ozden, SVP Clinical Development, becomes Chief Medical Officer on July 1, 2022.
- Goldstein enters consulting agreement from July 2022 to June 2023, renewable to 2026, at $6,000/month.
- Consulting agreement includes non-competition and non-solicitation provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/0001104659-22-069168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/tm2217977d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-069168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer